文献速递放疗物理与技术泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

基于稀疏无准直γ传感器网络的177Lu放射药物治疗连续临床前活性重建

Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated γ-Sensor Network.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-02-17

该临床前研究开发了一种低成本稀疏无准直γ传感器网络,利用治疗前扫描的肿瘤位置先验知识,在4只前列腺癌小鼠模型中重建177Lu-PSMA-617治疗后的实时肿瘤和危及器官活性。系统重建的肿瘤总活性和%IA/mL与小型动物SPECT高度线性相关(R2=0.991和0.994),采集与重建时间分辨率为1分钟,比常规小型动物SPECT快30倍以上。作者认为该系统可用于高时间分辨率临床前活性重建,并推动临床转化以通过频繁测量多肿瘤和危及器官的活性分布来改善177Lu-RPT的质量与安全性。

要点

  • 稀疏无准直γ传感器网络可在临床前模型中重建177Lu-PSMA-617的实时肿瘤和OAR活性。
  • 肿瘤总活性与%IA/mL重建结果与小型动物SPECT高度线性相关(R2=0.991和0.994)。
  • 1分钟时间分辨率比常规小型动物SPECT快30倍以上,可捕捉早期快速动力学。

核心结论

  • 该系统可用于高时间分辨率临床前活性重建,并推动临床转化以改善177Lu-RPT的质量与安全性。

研究设计与样本

  • 临床前方法学研究,使用填充[177Lu]Lu-PSMA-617的小型定制体模和4只携带2种人前列腺癌细胞系(PC3-PIP、PC3-flu)不同数量肿瘤的小鼠模型进行验证。
  • 利用治疗前扫描(如PET/CT)的肿瘤位置先验知识,开发低成本稀疏传感器网络重建实时肿瘤和OAR活性。
  • 在注射后10分钟、6小时、12小时、24小时和48小时于小鼠体外采集无准直γ计数。

主要发现

  • 系统重建的肿瘤、肾脏和膀胱总肿瘤活性及%IA/mL与小型动物SPECT高度线性相关(总活性R2=0.991,%IA/mL R2=0.994)。
  • 采集与重建以1分钟时间分辨率进行,比常规小型动物SPECT成像快30倍以上。
  • 该系统能够捕捉早期时间点的快速动力学,并以小型动物SPECT系统成本的一小部分创建接近连续的时间-活性曲线。

关键数值与推荐

  • 肿瘤总活性重建与小型动物SPECT的R2=0.991。
  • 肿瘤%IA/mL重建与小型动物SPECT的R2=0.994。
  • 时间分辨率为1分钟,比常规小型动物SPECT成像快30倍以上。

临床怎么用

  • 临床前研究中可利用稀疏无准直γ传感器网络以高时间分辨率频繁测量多肿瘤和OAR的活性分布。
  • 该系统成本低于小型动物SPECT,有望用于捕捉177Lu-RPT早期快速动力学。
  • 作者提示需进行临床适配以改善177Lu-RPT的质量与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 177Lu-based radiopharmaceutical therapy (RPT) has shown increasing promise in the treatment of neuroendocrine and metastatic prostate cancer. Delivering optimal radiation dose to tumors while minimizing dose to organs-at-risk (OAR) remains an unmet need because of significant patient-to-patient heterogeneity in treatment response, necessitating multiple snapshots of the in vivo activity distribution. Toward this goal, here we present a high temporal resolution activity reconstruction method demonstrated on preclinical prostate cancer models. METHODS AND MATERIALS: Using a priori knowledge of tumor locations from a pretherapy scan (eg, positron emission tomography/computed tomography), we have developed a low-cost, sparse sensor network to reconstruct the real-time tumor and OAR activity in preclinical cancer models. The proposed system was successfully validated with: (1) a small custom phantom filled with [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617; and (2) 4 mice models, bearing varying numbers of tumors from 2 human prostate cancer cell lines (PC3-PIP, PC3-flu), to which [177Lu]Lu-PSMA-617 RPT was administered. Uncollimated γ counts using the developed network were acquired outside of the mouse at 10 minutes post-injection, 6 hours, 12 hours, 24 hours, and 48 hours post-injection. RESULTS: The developed system's total tumor activity and percent injected activity per milliliter of tissue (%IA/mL) reconstruction in tumors, kidneys, and bladders is highly linear with the total tumor activity (R2 = 0.991) and %IA/mL (R2 = 0.994) from state-of-art small-animal single photon emission computed tomography (SPECT). Acquisition and reconstruction were performed at a 1-minute temporal resolution, >30 times faster than conventional small-animal SPECT imaging, allowing for the ability to capture fast kinetics at early time points and create close-to continuous time-activity curves at a fraction of the cost of small-animal SPECT systems. CONCLUSIONS: The system can be used for high temporal resolution preclinical activity reconstruction, and motivates clinical adaptation in order to improve 177Lu-based RPT quality and safety through frequent activity distribution measurements of multiple tumors and OAR.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lall R, Evans M, Seo Y, et al. Continuous, Preclinical Activity Reconstruction in 177Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated γ-Sensor Network. Int J Radiat Oncol Biol Phys. 2026. PMID: 41713513. doi:10.1016/j.ijrobp.2026.02.224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。